Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galderma Group AGXSWX:GALD -2.71%15 Equity-to-Asset is 0.61 as of Jun. 2026, which is at its 10-year median of 0.61. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Galderma Group AG ranks better than 50.6% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Galderma Group AG's Total Stockholders Equity for the quarter that ended in Jun. 2026 was CHF6,566 Mil. Galderma Group AG's Total Assets for the quarter that ended in Jun. 2026 was CHF10,811 Mil.
Therefore, Galderma Group AG's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.61.
The historical rank and industry rank for Galderma Group AG's Equity-to-Asset or its related term are showing as below:
XSWX:GALD'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.43 Med: 0.61 Max: 0.62
Current: 0.61
During the past 5 years, the highest Equity to Asset Ratio of Galderma Group AG was 0.62. The lowest was 0.43. And the median was 0.61.
XSWX:GALD's Equity-to-Asset is ranked better than 50.6% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs XSWX:GALD: 0.61
Galderma Group AG (XSWX:GALD) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Galderma Group AG Equity-to-Asset Related Terms
Galderma Group AG Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALD vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Galderma Group AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (XSWX:GALD) has a Equity-to-Asset of 0.61 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Galderma Group AG and its competitors. This is near median its historical median of 0.61. Over the past decade, Galderma Group AG's Equity-to-Asset has ranged from 0.43 to 0.62. According to the industry distribution chart, Galderma Group AG ranks #498 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 49.4%.
Is Galderma Group AG's Equity-to-Asset too high?
Galderma Group AG's current Equity-to-Asset of 0.61 is near median its 10-year median of 0.61. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 0.62. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Galderma Group AG's value of 0.61 is 0% at this industry median. Based on the distribution chart, Galderma Group AG ranks #498 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #498 out of 1008 companies for Equity-to-Asset. This puts Galderma Group AG in the upper half of its industry. The industry median Equity-to-Asset is 0.61. Galderma Group AG's value of 0.61 is 0% at this benchmark. Historically, Galderma Group AG's own Equity-to-Asset has ranged from 0.43 to 0.62 over the past decade. While the company's 10-year median is 0.61 vs. the industry median of 0.61, Galderma Group AG has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current Equity-to-Asset of 0.61 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current Equity-to-Asset is 0.61, which is near median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Equity-to-Asset of 0.61. The current Equity-to-Asset is 0.61, which is near median its 10-year median of 0.61 and 0% at the Drug Manufacturers industry median of 0.61. Galderma Group AG's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Equity-to-Asset is 0.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 
